News Archive 2008
Innocoll Receives Fast Track Designation for Gentamicin Surgical Implant.
The antibiotic surgical product may reduce incidence of surgical site infections and reduce post-operative cost and complications.
DEERFIELD, Ill./ASHBURN, Va., August 25, 2008 — Baxter Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, a division of Innocoll, Inc., granting Baxter exclusive rights to market and distribute the company’s gentamicin surgical implant in the United States. The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections (SSIs) in the United States. This agreement is expected to add to Baxter’s biosurgical portfolio by giving surgeons an innovative option to help reduce risk of postoperative complications of SSIs during surgery.
ASHBURN, Va., August 8, 2008 /PRNewswire/ -- -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of three ongoing phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain.
ASHBURN, Va., July 28th , 2008 /PRNewswire/ -- -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the third of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain, has commenced dosing.
ASHBURN, Va., July 21, 2008 /PRNewswire/ –– –Innocoll Inc. today announced that Anthony H. Wild, Ph.D. has been appointed to its board of directors.
ASHBURN, Va.,April 30, 2008 /PRNewswire/ -- -Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® GENTAMICIN TOPICAL for the treatment and prevention of infected diabetic foot ulcers, has commenced dosing.
ASHBURN, Va.,April 17, 2007 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the second of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® GENTAMICIN TOPICAL for the treatment and prevention of infected diabetic foot ulcers, has commenced dosing. CollaRx GENTAMICIN TOPICAL is a biodegradable and fully resorbable Gentamicin-Collagen Sponge formulated and manufactured using Innocoll's proprietary collagen-based drug delivery technology, CollaRx. Upon application to a wound, the product releases gentamicin, a broad-spectrum, aminoglycoside antibiotic (having a concentration-dependent mechanism of action), for local action. This achieves a high concentration of drug at the target tissue, while maintaining low systemic levels well below the toxicity threshold.
ASHBURN, Va.,March 13, 2008 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the second of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain, has commenced dosing.
ASHBURN, Va., February 19, 2008 /PRNewswire/ –– Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the second of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections, has commenced dosing.
ASHBURN, Va., January 4, 2008 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain, has commenced dosing.